Can first-trimester screening program detect women at high risk for gestational diabetes mellitus?

References

• Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005;29:190–194.
   PubMed Web of Science ®Google Scholar
• Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol 2000;182:589–594.
   PubMed Web of Science ®Google Scholar
• Sayin NC, Canda MT, Ahmet N, Arda S, Süt N, Varol FG. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Arch Gynecol Obstet 2008;277:47–53.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32:62–67.
   PubMed Web of Science ®Google Scholar
• Riskin-Mashiah S, Younes G, Damti A, Auslender R. First-trimester fasting hyperglycemia and adverse pregnancy outcomes. Diabetes Care 2009;32:1639–1643.
   PubMed Web of Science ®Google Scholar
• Beneventi F, Simonetta M, Lovati E, Albonico G, Tinelli C, Locatelli E, Spinillo A. First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes. Prenat Diagn 2011;31:523–528.
   PubMed Web of Science ®Google Scholar
• Pedersen JF, Sørensen S, Ruge S. Human placental lactogen and pregnancy-associated plasma protein A in first trimester and subsequent fetal growth. Acta Obstet Gynecol Scand 1995;74:505–508.
   PubMed Web of Science ®Google Scholar
• Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002;87:1762–1767.
   PubMed Web of Science ®Google Scholar
• Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004;191:1446–1451.
   PubMed Web of Science ®Google Scholar
• Montanari L, Alfei A, Albonico G, Moratti R, Arossa A, Beneventi F, Spinillo A. The impact of first-trimester serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A on the diagnosis of fetal growth restriction and small for gestational age infant. Fetal Diagn Ther 2009;25:130–135.
   PubMed Web of Science ®Google Scholar
• Mook-Kanamori DO, Steegers EA, Eilers PH, Raat H, Hofman A, Jaddoe VW. Risk factors and outcomes associated with first-trimester fetal growth restriction. JAMA 2010;303:527–534.
   PubMed Web of Science ®Google Scholar
• Morssink LP, Kornman LH, Hallahan TW, Kloosterman MD, Beekhuis JR, de Wolf BT, Mantingh A. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998;18:147–152.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Position statement: gestational diabetes mellitus. Diabetes Care 2003, 26(Suppl. 1):103–105.
   Google Scholar
• Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000;107:1271–1275.
   PubMed Web of Science ®Google Scholar
• Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005;25:949–953.
   PubMed Web of Science ®Google Scholar
• Huang T, Hoffman B, Meschino W, Kingdom J, Okun N. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. Prenat Diagn 2010;30:471–477.
   PubMed Web of Science ®Google Scholar
• Pedersen JF, Sørensen S, Mølsted-Pedersen L. Pregnancy-associated plasma protein A in first trimester of diabetic pregnancy and subsequent fetal growth. Acta Obstet Gynecol Scand 1998;77:932–934.
   PubMed Web of Science ®Google Scholar
• Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265–1270.
   PubMed Web of Science ®Google Scholar
• Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn 2003;23:990–996.
   PubMed Web of Science ®Google Scholar
• Madsen HN, Ekelund CK, Tørring N, Ovesen PG, Friis-Hansen L, Ringholm L, Petersen OB. Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers. Acta Obstet Gynecol Scand 2012;91:57–61.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 2005;25:927–929.
   PubMed Web of Science ®Google Scholar
• Tooke JE. Microvascular function in human diabetes. A physiological perspective. Diabetes 1995;44:721–726.
   PubMed Web of Science ®Google Scholar
• Plante GE, Chakir M, Ettaouil K, Lehoux S, Sirois P. Consequences of alteration in capillary permeability. Can J Physiol Pharmacol 1996;74:824–833.
   PubMed Web of Science ®Google Scholar
• Bartha JL, Wood J, Kyle PM, Soothill PW. The effect of metabolic control on fetal nuchal translucency in women with insulin-dependent diabetes: a preliminary study. Ultrasound Obstet Gynecol 2003;21:451–454.
   PubMed Web of Science ®Google Scholar
• Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–237.
   PubMed Web of Science ®Google Scholar
• Cuckle H. Fetal nuchal translucency test for Down’s syndrome. Lancet 1997;350:1629–30; author reply 1631.
   PubMedGoogle Scholar
• Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997;10:381–386.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down’s syndrome. Prenat Diagn 1997;17:821–829.
   PubMed Web of Science ®Google Scholar
• HAPO Study Cooperative Research Group, Metzger BE, Lowe ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MD, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Rngl J Med 2008;358:1991–2002.
   PubMed Web of Science ®Google Scholar